Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.73 |
| ▸ | GAA | P10253 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | BPTF | Q12830 | 3/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | PRKACG | P22612 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21605422 | 0.93 | MAPT (0.64) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL32682824 | 0.92 | MAPT (0.61) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL21605391 | 0.91 | MAPT (0.60) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL20922384 | 0.86 | ADORA1 (0.55) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL17194176 | 0.86 | ADORA1 (0.55) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL17194311 | 0.86 | ADORA1 (0.55) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL3347382 | 0.84 | MAPT (1.00) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL17194296 | 0.84 | ADORA1 (0.53) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL13037555 | 0.84 | ADORA1 (0.75) | MAPTGAAKDM4EBPTFADORA1 | |
| SCHEMBL13366491 | 0.82 | BPTF (0.72) | MAPTGAAKDM4EBPTFADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| EP-4665719-A1 | SMALL MOLECULE TREATMENT OF FATTY LIVER DISEASE AND HCC | ScandiEdge Therapeutics AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-10-24 | — | — | US | disclosed |
| WO-2024170693-A1 | SMALL MOLECULE TREATMENT OF FATTY LIVER DISEASE AND HCC | SCANDIEDGE THERAPEUTICS AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-4169925-A2 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169925-A2 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | Novartis AG (CH) | 2023-04-26 | — | — | EP | disclosed |
| EP-3810613-B1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-11 | — | — | EP | disclosed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006084869-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005120642-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR TREATING HYPERPROLIFERATIVE DISORDERS | ALTANA PHARMA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118071-A2 | TETRAHYDROPYRIDOTHIOPHENES | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | MAPT 1220/4885GAA 1882/4885KDM4E 3338/4885 |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | GLP1R, GCGR, GPR119 | MAPT 4468/4885GAA 1902/4885KDM4E 3893/4885 |
| US-20240352030-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | TPMT, SARS1, NLN | MAPT 1468/4885GAA 1913/4885KDM4E 3253/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | MAPT 4109/4885GAA 4720/4885KDM4E 3018/4885 |
| US-12012417-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | MAPT 1565/4885GAA 2109/4885KDM4E 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.